- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02015598
Antioxidant Carbocysteine Treatment in Obstructive Sleep Apnoea Syndrome
Comparison of Oral Intake of Antioxidant Carbocysteine and Nasal Continuous Positive Airway Pressure (CPAP) for Treating in Moderate and Severe Obstructive Sleep Apnoea Syndrome Patients : a Randomized Clinical Trial
Obstructive sleep apnoea syndrome (OSAS) is characterised by repeated episodes of upper airway occlusion during sleep.It can cause cycles of hypoxia reoxygenation. And it was postulated that intermittent hypoxia seems to resemble ischemia-reperfusion.Many study suggest that ischemia-reperfusion represents an oxidative stress causing increased generation of reactive oxygen species, especially superoxide anions.It is one of the most important mechanisms of cardiovascular diseases, including hypertension, coronary artery disease and cerebrovascular accident complication with OSAS.So many individuals approve OSAS is an Oxidative Stress disease.
Continuous positive airway pressure (CPAP) is the first-line of treatment method in moderate/severe OSA.But poor adherence to CPAP treatment is very common.The failure rate with CPAP treatment is more than 50%.So we are searching a new treatment for that patients. Carbocysteine is a antioxidant.It can not only scavenges the free radicals but also replenishes glutathione(GSH)which is has double antioxidant capacity. However, Carbocysteine is cheaper than other which has double antioxidant capacity drugs,such as N-acetylcysteine.The purpose is to evaluate efficacy of oral intake of Antioxidant Carbocysteine witch can reduce oxidative stress and improve the symptom of OSAS.It recover the imbalance in the oxidant-anti-oxidant status may reduce cardiovascular abnormalities in Patients with OSAS.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou,, Guangdong, China, 510120
- Guangzhou Institute of Respiratory Disease
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male in an age range of 18 to 65 years
- Obstructive Sleep Apnoea with an Apnea Hypopnea Index (AHI) of greater than or equal to 15 confirmed by polysomnography
- The patient is able to provide consent
- The patient were not receiving therapy for sleep apnoea,such CPAP or surgery.
Exclusion Criteria:
- Inability to tolerate Carbocysteine or CPAP
- Treatment with CPAP or surgery prior to or at the time of enrolment
- presence of active acute or chronic infection
- Patients with unstable cardiovascular diseases (unstable angina, myocardial infarction, stroke, or transient ischemic attacks), neuromuscular diseases, chronic respiratory diseases, peripheral vascular disease
- Using of steroidal , nonsteroidal anti-inflammatory, vasodilators ,lipid-lowering drugs,or other medications that lower oxidative stress.
- Intake of central relevant drugs, sedatives, or other drugs which impair sleep
- Unwilling to participate in the study
- Participation in another clinical study in the past 4 weeks
- Shift worker
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Carbocysteine
Carbocysteine , tablet ,250mg per one tablet , patients oral intake with 500mg .tid.(1500mg/day)
|
carbocisteine (2×250 mg, three times daily) for 6 weeks.
The tablets are provided by Baiyunshan Pharmaceutical, China.
patients will interviewed after 3 weeks to check their adherence to the study regimen by collecting and counting the number of remaining tablets, record adverse events, and refill study tablets for the next 3 weeks.
Other Names:
|
Active Comparator: Continuous Positive Airway Pressure
Continuous Positive Airway Pressure(CPAP),auto-CPAP(USA,Philips), patients use Nasal CPAP overnight.
|
Patients will interviewed after 3 weeks and the end of trial.We will check their compliance to device memory download , record adverse events and pressure .
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of polysomnography (PSG) parameters after oral intake of Carbocysteine treatment
Time Frame: after 6 weeks
|
The Carbocysteine group will oral intake of Carbocysteine 500mg,tid for 6 weeks.We will examine the compliance with the drugs by Recycling the rest of the tablets.We compare the improvement of PSG parameters,such as AHI ,oxygen desaturation index(ODI),oxyhemoglobin saturation.
|
after 6 weeks
|
Daytime sleepiness(EDS) after oral intake of Carbocysteine treatment
Time Frame: after 6 weeks
|
EDS is evaluated by Epworth Sleeping Scale(ESS) grade.ESS≥9 means EDS.The higher the ESS, the more daytime sleepiness they feel.
|
after 6 weeks
|
Change of Oxidative Stress after oral intake of Carbocysteine treatment
Time Frame: after 6 weeks
|
Biomarkers is measured from venous blood.The blood is collected in the morning .After centrifugation ,the supernatant was kept at -80 degree centigrade.
|
after 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate efficacy of oral intake of Antioxidant Carbocysteine in comparison to Nasal continuous positive airway pressure (CPAP) treatment .
Time Frame: after 6 weeks treatment
|
We will examine the compliance with CPAP device memory download.We will compare the two group by the PSG parameters ,ESS, and Biomarkers .
|
after 6 weeks treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of vascular function after oral intake of Antioxidant Carbocysteine
Time Frame: after 6 weeks after oral intake of Carbocysteine treatment
|
Vasoreactivity Testing Protocol and intima-media thickness is measured by high-resolution ultrasonography at baseline and 6 weeks after treatment.Vasoactive mediators from blood will be studied.
|
after 6 weeks after oral intake of Carbocysteine treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: NuoFu Zhang, professor, Guangzhou Institute of Respiratory Disease
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Signs and Symptoms, Respiratory
- Sleep Apnea Syndromes
- Sleep Apnea, Obstructive
- Apnea
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Respiratory System Agents
- Expectorants
- Carbocysteine
Other Study ID Numbers
- IRD201319
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Sleep Apnoea
-
Papworth Hospital NHS Foundation TrustIceni Labs Ltd, Warwickshire, United KingdomCompletedObstructive Sleep Apnoea | Sleep ApnoeaUnited Kingdom
-
Heart and Diabetes Center North-Rhine WestfaliaCompletedObstructive Sleep Apnoea | Cheyne Stokes Respiration | Central Sleep ApnoeaGermany
-
University of British ColumbiaCompleted
-
University of CreteCompleted
-
University of ZurichCompletedObstructive Sleep ApnoeaSwitzerland
-
ResMedCompletedObstructive Sleep Apnoea (OSA)Australia
-
ResMedCompleted
-
Air Liquide Santé InternationalClinactRecruitingObstructive Sleep Apnoea Syndrome (OSAS)Portugal
-
Chinese University of Hong KongCompleted
-
Fundación Neumologica ColombianaUniversidad de la SabanaUnknownObstructive Sleep ApnoeaColombia
Clinical Trials on Carbocysteine
-
Belfast Health and Social Care TrustQueen's University, BelfastRecruitingRandomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis (CLEAR) (CLEAR)BronchiectasisUnited Kingdom
-
Clalit Health ServicesAboca Spa Societa' AgricolaCompletedComparison of Efficacy and Tolerability of Two Cough Syrups in Cough Due to Cold in Children. (URTI)Cough | Upper Respiratory Tract InfectionIsrael
-
Dompé Farmaceutici S.p.ACross Research S.A.Completed